Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Kristina Pilekær Sørensen, Mads Thomassen, Martin Bak, Qihua Tan, Torben A Kruse, Anne Vibeke Lænkholm, Martin Jakob Larsen, Mette K. Andersen, Anne-Marie Gerdes
Publikováno v:
Larsen, M J, Thomassen, M, Tan, Q, Lænkholm, A V, Bak, M, Sørensen, K P, Andersen, M K, Kruse, T A & Gerdes, A-M 2014, ' RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families ', B M C Medical Genomics, vol. 7, 9, pp. 9 . https://doi.org/10.1186/1755-8794-7-9
BMC Medical Genomics
BMC Medical Genomics
BACKGROUND: In more than 70% of families with a strong history of breast and ovarian cancers, pathogenic mutation in BRCA1 or BRCA2 cannot be identified, even though hereditary factors are expected to be involved. It has been proposed that tumors wit
Autor:
Kari Nousiainen, Anne Kallioniemi, Sampsa Hautaniemi, Lilli Saarinen, Alejandra Rodriguez-Martinez, Johanna Ketolainen, Emma-Leena Alarmo
Publikováno v:
BMC Medical Genomics
BMC Medical Genomics, Vol 4, Iss 1, p 80 (2011)
BMC Medical Genomics, Vol 4, Iss 1, p 80 (2011)
Background Bone morphogenetic proteins (BMPs) are members of the TGF-beta superfamily of growth factors. They are known for their roles in regulation of osteogenesis and developmental processes and, in recent years, evidence has accumulated of their
Autor:
Zahraa Haidar, Nadine Jalkh, Eliane Chouery, Makia J. Marafie, Christina Khater, Fahd Al-Mulla, Mohammed R. Al-Mulla, André Mégarbané, David Atallah, Hamad Ali
Publikováno v:
BMC Medical Genomics
Background Familial breast cancer (BC) represents 5 to 10% of all BC cases. Mutations in two high susceptibility BRCA1 and BRCA2 genes explain 16–40% of familial BC, while other high, moderate and low susceptibility genes explain up to 20% more of
Autor:
Stéphane Chrétien, Mario Campone, Wilfried Gouraud, Hamza Lasla, Catherine Guérin-Charbonnel, Zein Sharif, Loïc Campion, Pascal Jézéquel
Publikováno v:
BMC Medical Genomics
BMC Medical Genomics, BioMed Central, 2015, 8, pp.80. ⟨10.1186/s12920-015-0153-6⟩
BMC Medical Genomics, 2015, 8, pp.80. ⟨10.1186/s12920-015-0153-6⟩
BMC Medical Genomics, BioMed Central, 2015, 8, pp.80. ⟨10.1186/s12920-015-0153-6⟩
BMC Medical Genomics, 2015, 8, pp.80. ⟨10.1186/s12920-015-0153-6⟩
Background Breast cancer biological characteristics change as age advances. Today, there is a lack of knowledge regarding age-specific molecular alterations that characterize breast tumours, notably in elderly patients. The vast majority of studies t
Autor:
C. Marcelo Aldaz, Frances S. Kittrell, Yun Zhang, Reid P. Bissonnette, Jamal Hill, Sally Gaddis, Martín Carlos Abba, Daniel Medina, Yuhui Hu, Carla C. Levy, Powel H. Brown
Publikováno v:
SEDICI (UNLP)
Universidad Nacional de La Plata
instacron:UNLP
BMC Medical Genomics
BMC Medical Genomics, Vol 1, Iss 1, p 40 (2008)
Universidad Nacional de La Plata
instacron:UNLP
BMC Medical Genomics
BMC Medical Genomics, Vol 1, Iss 1, p 40 (2008)
Background: The rexinoid bexarotene (LGD1069, Targretin) is a highly selective retinoid × receptor (RXR) agonist that inhibits the growth of pre-malignant and malignant breast cells. Bexarotene was shown to suppress the development of breast cancer
Publikováno v:
BMC Medical Genomics
Background The molecular characteristics of human diseases are often represented by a list of genes termed “signature genes”. A significant challenge facing this approach is that of reproducibility: signatures developed on a set of patients may f
Publikováno v:
BMC Medical Genomics
BMC Medical Genomics, Vol 5, Iss 1, p 16 (2012)
BMC Medical Genomics, Vol 5, Iss 1, p 16 (2012)
Background The efficacy of chemotherapy regimens in breast cancer patients is variable and unpredictable. Whether individual patients either achieve long-term remission or suffer recurrence after therapy may be dictated by intrinsic properties of the
Publikováno v:
BMC Medical Genomics, Vol 2, Iss 1, p 69 (2009)
BMC MEDICAL GENOMICS
BMC Medical Genomics
BMC MEDICAL GENOMICS
BMC Medical Genomics
Background Microarray technology has allowed to molecularly characterize many different cancer sites. This technology has the potential to individualize therapy and to discover new drug targets. However, due to technological differences and issues in